Scholarlink

<p>Osteosarcoma is the most common primary bone tumor, which is associated with a high mortality rate. The <i>c-Fos</i> transgenic mouse model has been described to spontaneously develop osteosarcoma, and the ribosomal S6 kinase 2 (Rsk2) was found to be essential for c-Fos-induced osteosarcoma formation in mice. By isolating and characterizing osteosarcoma cell lines from <i>Fos</i>Tg and <i>Fos</i>Tg;<i>Rsk2</i><sup>−/y</sup> mice, we observed that Rsk2 deficiency impairs the growth advantage of <i>Fos</i>Tg cells. This can be explained by the aberrant number of nuclei due to impaired cytokinesis, inducing mitotic catastrophe. We therefore tested a pharmacological Rsk inhibitor (BI-D1870) for its ability to inhibit the proliferation of osteosarcoma cells and found that the effects observed by genetic Rsk2 inactivation were mimicked. BI-D1870 administration to <i>Fos</i>Tg cell lines led to reduced expression of Aurora kinase B. Therefore, the influence of a pharmacological Aurora kinase B inhibitor (Hesperadin) was tested. Similar to BI-D1870, Hesperadin caused impaired cytokinesis, resulting in the accumulation of polynuclear cells. This effect was also observed for two human osteosarcoma cell lines, U2OS and SaOS-2. Based on our findings, Rsk2 and/or Aurora kinase B can serve as potential targets for the design of new osteosarcoma therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rsk2 inhibition induces an aneuploid post-mitotic arrest of cell cycle progression in osteosarcoma cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月10日

查看全文
  • Armelle Carreau,
  • Christina Baldauf,
  • Lena Warlich,
  • Magdalena Weingartner,
  • Laura Brylka,
  • Michael Amling,
  • Thorsten Schinke,
  • Julia Luther

摘要

Osteosarcoma is the most common primary bone tumor, which is associated with a high mortality rate. The c-Fos transgenic mouse model has been described to spontaneously develop osteosarcoma, and the ribosomal S6 kinase 2 (Rsk2) was found to be essential for c-Fos-induced osteosarcoma formation in mice. By isolating and characterizing osteosarcoma cell lines from FosTg and FosTg;Rsk2−/y mice, we observed that Rsk2 deficiency impairs the growth advantage of FosTg cells. This can be explained by the aberrant number of nuclei due to impaired cytokinesis, inducing mitotic catastrophe. We therefore tested a pharmacological Rsk inhibitor (BI-D1870) for its ability to inhibit the proliferation of osteosarcoma cells and found that the effects observed by genetic Rsk2 inactivation were mimicked. BI-D1870 administration to FosTg cell lines led to reduced expression of Aurora kinase B. Therefore, the influence of a pharmacological Aurora kinase B inhibitor (Hesperadin) was tested. Similar to BI-D1870, Hesperadin caused impaired cytokinesis, resulting in the accumulation of polynuclear cells. This effect was also observed for two human osteosarcoma cell lines, U2OS and SaOS-2. Based on our findings, Rsk2 and/or Aurora kinase B can serve as potential targets for the design of new osteosarcoma therapies.